Vaccines against Mpox: Combating the Threat
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Epidemiology".
Deadline for manuscript submissions: 15 December 2024 | Viewed by 1886
Special Issue Editor
Interests: emerging viral diseases; virology; epidemiology
Special Issue Information
Dear Colleagues,
Vaccinology dates back to the times when viruses were not known, and the first vaccine was developed to combat smallpox. Since then, our understanding of the host adaptive immune responses to infectious diseases has led to the development of a variety of vaccine platforms and vaccine technologies to prevent morbidity and mortality from a wide range of infectious diseases. Some of these technologies are well established while some others are still under development.
In this Special Issue, we shed light onto the latest advances in the field of vaccines against orthopoxviruses, with focus on mpox, which still causes outbreaks at the global level and has a significant impact, including in children, in endemic settings.
Dr. Lorenzo Subissi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine efficacy
- monkeypox
- mpox
- smallpox
- immunity
- surveillance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
